Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Yair Lotan MD

Yair Lotan MD

Professor and Chief of Urologic Oncology, Jane and John Justin Distinguished Chair in Urology, In Honor of Claus G. Roehrborn, MD, Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, Texas
Dr. Lotan is the Professor of the Department of Urology at UT Southwestern and holder of the Helen J. and Robert S. Strauss Professorship in Urology, his practice focuses on oncology and endourology.  Dr. Lotan's research is focused on the areas of bladder cancer screening, biomarkers, decision analysis, and health economics.He has participated in multiple collaborative studies involving early detection of bladder cancer and evaluation of molecular markers. His goal is to improve diagnosis and management of bladder cancer as well as identify patients at risk for recurrence and progression. He has been a co-investigator on several NIH funded trials evaluating urine based tumor markers.He is the PI on several investigator-initiated studies evaluating the role of urine and tissue markers in management of bladder cancer. He has also been involved in writing guidelines for the management of bladder cancer and chairing meetings focused on bladder cancer.He has published over 450 peer reviewed papers and multiple reviews and book chapters.

Disclosures

  • Abbott: Scientific study or trial
  • Cepheid: Consultant/advisor
  • Pacific Edge: Scientific study or trial
  • FKD: Scientific study or trial
  • MDxHealth: Consultant/advisor, scientific study
  • Biocancell: Scientific study or trial
  • GenomeDx Biosciences, Inc.: Scientific study or trial
  • Photocure: Consultant/advisor, scientific study or trial
  • Urogen: Other
  • Astra-Zeneca: Consultant/advisor
  • Vessi Medical: Leadership position

Recent Contributions to PracticeUpdate:

  1. Multiple Recurrences and Disease Progression in Patients With Intermediate-Risk NMIBC
  2. Photodynamic Diagnosis–Guided Laser Destruction of Bladder Tumors vs Transurethral Tumor Resection in Patients With Recurrent Intermediate-Risk Low-Grade Bladder Tumors
  3. Effect of Perioperative Continuation of Anticoagulants on the Intraoperative Blood Loss and Blood Transfusion Rates in Patients Undergoing Radical Cystectomy
  4. Fluorescent Urine Cytology for Screening and Surveillance of Bladder Cancer
  5. New American Urological Association Guidelines for Risk Classification of Hematuria
  6. Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non–Muscle-Invasive Bladder Cancer
  7. Immuno-Oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous Cell Carcinoma of the Bladder
  8. Intravesical Combination Gemcitabine/Docetaxel for Non–Muscle Invasive Bladder Cancer
  9. Bladder Mapping of Tumor Recurrence After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
  10. Dusting vs Fragmentation With Extraction

Recently Updated